Group 1: Company Overview - Xero Ltd, founded in 2006 by Rod Drury in Wellington, New Zealand, provides cloud-based accounting software primarily for accountants and bookkeepers to assist small business customers [1][2] - Goodman Group, established in 1989, is a leading global property group that owns, develops, and manages real estate assets across multiple continents, operating in key markets including Australia, New Zealand, the UK, Japan, the US, and Brazil [3] Group 2: Share Price Performance - Xero's share price has decreased by 6.2% since the beginning of 2025, while Goodman Group's share price is currently 32.8% above its 52-week lows [1] - Xero shares have a price-to-sales ratio of 16.51x, which is lower than its 5-year average of 18.65x, indicating that the shares may be undervalued or that sales have increased [5] Group 3: Valuation Metrics - The trailing dividend yield for Goodman Group is approximately 0.90%, compared to its 5-year average of 1.28%, suggesting a potential decrease in dividend stability [6] - Valuation methods such as Discounted Cash Flow (DCF) and Dividend Discount Models (DDM) are available for assessing the value of companies like Xero and Goodman Group [7]

Group 1: James Hardie Industries - James Hardie Industries is a building solutions company and the world's largest producer of fibre cement and gypsum products, operating across North America, Europe, Australia, and New Zealand with over 5,200 employees [1] - The share price of James Hardie Industries (ASX:JHX) has decreased by approximately 41.8% since the beginning of 2025 [1] - Currently, James Hardie Industries plc shares have a price-sales ratio of 2.77x, which is lower than its 5-year average of 4.14x, indicating that the shares are trading below historical averages despite revenue growth over the last three years [7] Group 2: CSL Limited - CSL is a global biotechnology company focused on creating and delivering life-saving medicines, with a mission to protect public health and improve the quality of life for individuals with life-threatening conditions [3] - The company operates through three main divisions: CSL Behring, which manufactures blood plasma products; CSL Seqirus, which develops flu-related products; and CSL Vifor, specializing in iron deficiency and nephrology [4] - CSL has established a strong reputation among Australian investors for reliability and consistent dividend payouts, making it a favored choice for those seeking exposure to the growing healthcare sector [5] - CSL is currently paying a trailing dividend yield of around 1.95%, which is higher than its 5-year average of 1.50%, indicating stability and the ability to provide income [8]